Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum
JAMA Neurology · 01.03.2025 · 82 (3) · 285
DOI: 10.1001/jamaneurol.2024.4643 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Neurology, erschienen am 01.03.2025. Verfasst von Daniel Ferreira und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Geriatrics, Center for Alzheimer's Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stoc…. Hauptthemen laut MEDLINE: Lewy Body Disease, Positron-Emission Tomography, Fluorodeoxyglucose F18, Cognitive Dysfunction. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Although 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized.
Objective
To investigate longitudinal FDG-PET in prodromal DLB and DLB, including a subsample with autopsy data, and report estimated sample sizes for a hypothetical clinical trial in DLB. Design, Setting, and Participants Longitudinal case-control study with mean (SD) follow-up of 3.8 (2.3) years. Cases were recruited consecutively between 2007 and 2022 at a referral center and among the population. Patients with probable DLB or mild cognitive impairment with Lewy bodies (MCI-LB) were included. Individuals without cognitive impairment were included from a population-based cohort balanced on age and sex for comparison. All participants completed at least 1 follow-up assessment by design. Exposure Patients with MCI-LB and DLB. Main Outcomes and Measures Rate of change in FDG-PET was assessed as standardized uptake value ratios (SUVr). Clinical progression was assessed with the Clinical Dementia Rating Sum of Boxes (CDR-SB) score.
Results
Thirty-five patients with probable DLB, 37 patients with MCI-LB, and 100 individuals without cognitive impairment were included. The mean (SD) age of the DLB and MCI-LB groups combined (n = 72) was 69.6 (8.2) years; 66 patients (92%) were men and 6 (8%) were women. At follow-up, 18 participants (49%) with MCI-LB had progressed to probable DLB. Patients with MCI-LB had a faster decline in FDG-SUVr, compared with that of participants without cognitive impairment, in the posterior cingulate, occipital, parietal, temporal, and lateral frontal cortices. The same regions showed greater metabolic decline in patients with DLB than in participants without cognitive impairment, with the addition of anterior-middle cingulate, insula, and medial frontal orbital cortices. Rates of change in FDG-PET in these brain regions were combined into a region of interest (ROI) labeled longitudinal FDG-PET LB meta-ROI. The rate of change in FDG-SUVr in the meta-ROI correlated with the rate of change in CDR-SB, and sample size estimates were reported for potential clinical trials in DLB. Findings were confirmed in the subsample with neuropathologic confirmation (n = 20). Conclusions and Relevance This study found that brain hypometabolism begins to evolve during the prodromal stages of DLB with changes paralleling symptomatic progression. These data may inform clinical practice and trials planning to use FDG-PET for biologic staging, monitoring disease progression, and potentially assessing treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Geriatrics, Center for Alzheimer's Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota.
- Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Santa María de Guía, Las Palmas, España.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
- Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Zitieren
APA
Ferreira, D., Przybelski, S. A., Lesnick, T. G., Diaz-Galvan, P., Schwarz, C. G., Murray, M. M., Dickson, D. W., Nguyen, A., Reichard, R. R., Senjem, M. L., Gunter, J. L., Jack, C. R., Min, P. H., Jain, M. K., Miyagawa, T., Forsberg, L. K., Fields, J. A., Savica, R., Graff-Radford, J., …, & Kantarci, K. (2025). Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum. JAMA Neurology, 82(3), 285. https://doi.org/10.1001/jamaneurol.2024.4643
Vancouver
Ferreira D, Przybelski SA, Lesnick TG, Diaz-Galvan P, Schwarz CG, Murray MM, et al. Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum. JAMA Neurology. 2025;82(3):285. doi:10.1001/jamaneurol.2024.4643
BibTeX
@article{Ferreira2025,
author = {Ferreira, Daniel and Przybelski, Scott A and Lesnick, Timothy G and Diaz-Galvan, Patricia and Schwarz, Christopher G and Murray, Melissa M and Dickson, Dennis W and Nguyen, Aivi and Reichard, Ross R and Senjem, Matthew L and Gunter, Jeffrey L and Jack, Clifford R and Min, Paul H and Jain, Manoj K and Miyagawa, Toji and Forsberg, Leah K and Fields, Julie A and Savica, Rodolfo and Graff-Radford, Jonathan and Ramanan, Vijay K and Jones, David T and Botha, Hugo and St Louis, Erik K and Knopman, David S and Graff-Radford, Neill R and Day, Gregory S and Ferman, Tanis J and Kremers, Walter K and Petersen, Ronald C and Boeve, Bradley F and Lowe, Val J and Kantarci, Kejal},
title = {Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum},
journal = {JAMA Neurology},
year = {2025},
volume = {82},
number = {3},
pages = {285},
doi = {10.1001/jamaneurol.2024.4643}
}
EUVIMED